(Q36432119)

14 August 2017

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma (English)

1 reference

14 August 2017

0 references

budesonide/formoterol

1 reference

A H Morice

1

1 reference

14 August 2017

S Peterson

series ordinal

2

1 reference

14 August 2017

O Beckman

series ordinal

3

1 reference

14 August 2017

D Osmanliev

series ordinal

4

1 reference

14 August 2017

language of work or name

1 reference

20 September 2007

1 reference

International Journal of Clinical Practice

14 August 2017

1 reference

14 August 2017

61

1 reference

14 August 2017

11

1 reference

14 August 2017

1874-1883

1 reference

Performance of Turbuhaler((R)) in Patients with Acute Airway Obstruction and COPD, and in Children with Asthma : Understanding the Clinical Importance of Adequate Peak Inspiratory Flow, High Lung Deposition, and Low In Vivo Dose Variability

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Problems with inhaler use: a call for improved clinician and patient education

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

The CFC to HFA transition and its impact on pulmonary drug development

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Budesonide/formoterol: a review of its use in asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study

28 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2007.01574.X

Prolonged airway activity and improved selectivity of budesonide possibly due to esterification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2007.01574.X

Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2007.01574.X

Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Validation of a standardized version of the Asthma Quality of Life Questionnaire

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2228375

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

21 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-1241.2007.01574.X

Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group

21 January 2018

1 reference

12 December 2020

Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue

1 reference

12 December 2020

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma

1 reference

12 December 2020

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

1 reference

12 December 2020

The inhalation device influences lung deposition and bronchodilating effect of terbutaline

1 reference

12 December 2020

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI

1 reference

12 December 2020

Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI

1 reference

12 December 2020

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

12 December 2020

10.1111/J.1742-1241.2007.01574.X

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/avibjdf7anb5dltqjnwk7wsv5u

30 July 2022

release_avibjdf7anb5dltqjnwk7wsv5u

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/avibjdf7anb5dltqjnwk7wsv5u

30 July 2022

https://api.fatcat.wiki/v0/release/avibjdf7anb5dltqjnwk7wsv5u

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/avibjdf7anb5dltqjnwk7wsv5u

PubMed publication ID

1 reference

30 July 2022